Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 4/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNG | P07510 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CHRND | Q07001 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.45 |
| ▸ | FCER2 | P06734 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909650 | 0.89 | PARP1 (0.47) | ITGB3ITGA2BPARP1PARP3HPGDS | |
| SCHEMBL26034243 | 0.89 | PARP1 (0.47) | ITGB3ITGA2BPARP1PARP3HPGDS | |
| SCHEMBL22472727 | 0.85 | ITGB3 (0.50) | ITGB3ITGA2BCHRNA1CHRNGCHRNB1 | |
| SCHEMBL17178203 | 0.83 | CHRNA1 (0.44) | ITGB3ITGA2BPARP1PARP3HPGDS | |
| SCHEMBL3148220 | 0.82 | CTSG (0.54) | ITGB3ITGA2BPARP1PARP3HPGDS | |
| SCHEMBL16330787 | 0.81 | CHRNA1 (0.45) | ITGB3ITGA2BHPGDSCHRNA1CHRNG | |
| SCHEMBL26425109 | 0.79 | MME (0.56) | PARP1PARP3HPGDSACEMMP1 | |
| SCHEMBL1329813 | 0.79 | CTSC (0.59) | PARP1PARP3HPGDSMMP1FCER2 | |
| SCHEMBL1329814 | 0.79 | CTSC (0.59) | PARP1PARP3HPGDSMMP1FCER2 | |
| SCHEMBL8258217 | 0.78 | PSMB5 (0.58) | ITGB3ITGA2BPARP1PARP3HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170151339-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151339-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | CD47, CD44, FURIN | ITGB3 557/4885ITGA2B 362/4885PARP1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.